EFMC-ACSMEDI MedChem Frontiers 2019

Confirmed Speakers


Plenary Speakers

First Time Disclosure
The Discovery of LML134, a Histamine H3 Receptor Inverse Agonist for the Clinical Treatment of Excessive Sleep Disorders (IL09)
Dr Yves P. AUBERSONDr Yves P. AUBERSON
(NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, Basel, Switzerland)

Read more
Derivatives of 1,3,5-triazine as a New Trend in the Search for the 5-HT6 Receptor Ligands with Therapeutic Perspectives (PL01)
Dr Jadwiga HANDZLIKDr Jadwiga HANDZLIK
(MEDICAL COLLEGE OF JAGIELLONIAN UNIVERSITY, Krakow, Poland)

Read more
Systems Pharmacology Links GPCRs with Retinal Degenerative Disorders (PL02)
Prof. Krzysztof  PALCZEWSKIProf. Krzysztof PALCZEWSKI
(CASE WESTERN RESERVE UNIVERSITY, Cleveland, United States)

Read more
Next Generation Pain Therapeutics for the Opioid Crisis: Design of Bifunctional Nociceptin/Mu Opioid GPCR Ligands as non-Addicting Analgesics (PL03)
Dr Nurulain ZAVERIDr Nurulain ZAVERI
(ASTRAEA THERAPEUTICS, Mountain View, United States)

Read more

Matrix Metallo-Proteinases

Libraries of Fluorogenic Substrates with Natural and Unnatural Amino Acids as a Tool in Design of Active and Specific Probes for Investigation of Proteolytic Enzymes (IL01)
Prof. Marcin DRAGProf. Marcin DRAG
(WROCLAV UNIVERSITY OF TECHNOLOGY, Wroclaw, Poland)

Read more
MMP-9 at the Synapse in the Brain and Mind (IL02)
Prof. Leszek KACZMAREKProf. Leszek KACZMAREK
(NENCKI INSTITUTE OF EXPERIMENTAL BIOLOGY, Warsaw, Poland)

Read more
Metalloproteinase Cleavage Control of Interferon Alpha and Gamma Dampens Inflammation and Anti-Viral Immunity (IL03)
Prof. Christopher OVERALLProf. Christopher OVERALL
(UNIVERSITY OF BRITISH COLUMBIA, Vancouver, Canada)

Read more

Chemical Biology Tools & Target Engagement Technologies

Protein-Ligand Interactions: How Medicinal Chemistry Contributes to the Understanding of Molecular Recognition (IL17)
Dr Marc NAZAREDr Marc NAZARE
(FMP, Berlin, Germany)

Read more
Adventures in Targeting Protein Lipdation: Breaking Drug Resistance Using Fragment Deconstruction and Chemical Biology (IL18)
Prof. Edward TATEProf. Edward TATE
(IMPERIAL COLLEGE LONDON, London, United Kingdom)

Read more
Tankyrase Inhibitors : Evidence for Therapeutic Potential in Immuno-Oncology
Dr Luc VAN HIJFTEDr Luc VAN HIJFTE
(SCT & MERCACHEM-SYNCOM, Nijmegen, The Netherlands)

GPCRs: a Discovery Powerhouse

Design of Orexin 1 Receptor Selective Antagonists (IL11)
Dr Uta LESSELDr Uta LESSEL
(BOEHRINGER INGELHEIM, Biberach an der Riss, Germany)

Read more
Next Generation GPR119 Agonists as Potential Treatment for Cardiometabolic Diseases (IL12)
Dr Lothar SCHWINKDr Lothar SCHWINK
(SANOFI, Frankfurt Am Main, Germany)

Read more
G Protein-Coupled Receptors: the Structural Basis for their Pharmacology (IL10)
Dr Chris TATEDr Chris TATE
(MRC LABORATORY OF MOLECULAR BIOLOGY, Cambridge, United Kingdom)

Read more

Genomics in Drug Discovery : Roles for Chemistry

Designing Synthetic Gene Regulators (SynGR) (IL04)
Prof. Aseem ANSARIProf. Aseem ANSARI
(UNIVERSITY OF WISCONSIN-MADISON, Madison, United States)

Read more
Exploring Bacterial Genomes for Natural Product Discovery and Development (IL05)
Prof. Alessandra S.  EUSTAQUIOProf. Alessandra S. EUSTAQUIO
(UNIVERSITY OF ILLINOIS AT CHICAGO, Chicago, United States)

Read more
Integrative Screening Identifies a Novel Node in the Oncogenic YAP/HIPPO Pathway (IL06)
Dr Mathias FREDERIKSENDr Mathias FREDERIKSEN
(NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH (NIBR), Basel, Switzerland)

Specific and Multi-Targeted Drugs

Charting New Paths in Multi-Target Drug Discovery for Alzheimer’s Disease (IL13)
Prof. Maria Laura BOLOGNESIProf. Maria Laura BOLOGNESI
(UNIVERSITY OF BOLOGNA, Bologna, Italy)

Read more
Chemical Biology for Drug Discovery: A Click and Play Approach Exemplified by ERK1/2 Probes (OC03)
Dr Charlotte GRIFFITHS-JONESDr Charlotte GRIFFITHS-JONES
(ASTEX PHARMACEUTICALS, Cambridge, United Kingdom)

Read more
Identification and in-vivo Efficacy Studies of a Nicotinamide Derivative as Novel NNMT Inhibitor (OC04)
Dr Sven RUFDr Sven RUF
(SANOFI-AVENTIS DEUTSCHLAND GMBH, Frankfurt am Main, Germany)

Read more
Multiple Targeting - The Histamine H3 Receptor Pharmacophore as Central Element (IL14)
Prof. Holger STARKProf. Holger STARK
(HEINRICH HEINE UNIVERSITY DÜSSELDORF, Duesseldorf, Germany)

Read more

Targeted Covalent Inhibitors

Mining the Protein Kinase Cysteinome (IL22)
Dr Tjeerd BARFDr Tjeerd BARF
(ACERTA PHARMA BV, Oss, The Netherlands)

Read more
Safety First: Covalent Inhibitors from a Safety Perspective (IL20)
Dr Mickael MOGEMARKDr Mickael MOGEMARK
(ASTRAZENECA, Mölndal, Sweden)

Read more
Adventures in Functional Assignment and Inhibition of Metallo-Enzymes (IL21)
Prof. Christopher J. SCHOFIELDProf. Christopher J. SCHOFIELD
(UNIVERSITY OF OXFORD, Oxford, United Kingdom)

Read more

Adding AI to the Drug Discovery Tool Box

Capturing and Applying Knowledge to Guide Compound Optimisation (OC10)
Mr Nick FOSTERMr Nick FOSTER
(OPTIBRIUM, United Kingdom)

Read more
Learning the Art of Chemical Synthesis with Deep Neural Networks and Discipline Scale Data (IL23)
Prof. Mark WALLERProf. Mark WALLER
(UNIVERSITY OF WOLLONGONG, Wollongong, Australia)

Read more
Applications of Artificial Intelligence in Drug Discovery – Separating Hype From Utility (IL24)
Dr Pat WALTERSDr Pat WALTERS
(RELAY THERAPEUTICS, Cambridge, United States)

Read more
Augmented Intelligence for Compound Design (OC09)
Dr Michal WARCHOLDr Michal WARCHOL
(ARDIGEN, Krakow, Poland)

Read more

Advances in Protein Degradation Technologies

Targeted Protein Degradation with Small Molecules: how PROTACs Work (IL07)
Prof. Alessio CIULLIProf. Alessio CIULLI
(UNIVERSITY OF DUNDEE, Dundee, United Kingdom)

Read more
Drugging Challenging E3 Ligases: A Novel Multidisciplinary Approach to Identify Small-Molecules that Bind FBW7 (OC02)
Ms Miriam MARTINEZ CARTROMs Miriam MARTINEZ CARTRO
(UNIVERSITY OF BARCELONA, Barcelona, Spain)

Read more
The Ubiquitin System (IL08)
Prof. Huib OVAAProf. Huib OVAA
(LEIDEN UNIVERSITY MEDICAL CENTER, Leiden, The Netherlands)

Read more
Small-Molecule Modulation of Cereblon Protein Level (OC01)
Mr Christian STEINEBACHMr Christian STEINEBACH
(UNIVERSITY OF BONN, Bonn, Germany)

Read more

Opioid, Pain, Endo-Cannabinoid

The Discovery and Development of the Clinical FAAH Inhibitor JNJ-42165279 (OC06)
Prof. James BREITENBUCHERProf. James BREITENBUCHER
(UNIVERSITY OF CALIFORNIA SAN FRANCISCO, San Francisco, United States)

Read more
Potential of Natural Cannabinoids and Synthetic Cannabinoids in Neuroprotection (IL16)
Prof. Rafael FRANCOProf. Rafael FRANCO
(UNIVERSITY OF BARCELONA, Barcelona, Spain)

Read more
Cannabinoid Receptor Type 2 Modulation to Improve Outcomes for Cartilage Repair in the Osteoarthritic Joint (IL15)
Prof. Katarzyna STAROWICZ-BUBAKProf. Katarzyna STAROWICZ-BUBAK
(INSTITUTE OF PHARMACOLOGY, POLISH ACADEMY OF SCIENCES, Krakow, Poland)

Read more
Discovery of Best in-class, Novel, Selective, Potent and Peripheral FLT3 Inhibitors, a New Way to Treat Neuropathic Pain (OC05)
Dr Dominique SURLERAUXDr Dominique SURLERAUX
(BCI PHARMA, Liège, Belgium)

Read more

Pharma Research Highlights in Poland

Discovery of OAT-2068 - A Potent, Selective, Orally Bioavailable Inhibitor of Mouse Chitotriosidase and its In Vivo Activity in the Bleomycin-Induced Pulmonary Fibrosis Model in Mice (OC07)
Dr Agnieszka BARTOSZEWICZDr Agnieszka BARTOSZEWICZ
(ONCOARENDI THERAPEUTICS SA, Warszawa, Poland)

Read more
DPD-inspired Small Heterocyclic Libraries Characterized as Novel LsrK Kinase Inhibitors: an Opportunity to Fight Antimicrobial Resistance (OC08)
Dr Anna KARAWAJCZYKDr Anna KARAWAJCZYK
(SELVITA, Krakow, Poland)

Jointly Organised by

Local Organiser

Bronze Sponsors

Copyright 2020 LD Organisation srl  |  rue Michel de Ghelderode 33/02 B-1348  Louvain-la-Neuve (Belgium)  Tel. +32 (0)10 45 47 77  |   |  VAT: BE 0464819842
Developed and powered by Antalys